Related references
Note: Only part of the references are listed.Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study
K. Reich et al.
BRITISH JOURNAL OF DERMATOLOGY (2021)
A Phase IV, Randomized, Double-Blind, Placebo-Controlled Crossover Study of the Effects of Ustekinumab on Vascular Inflammation in Psoriasis (the VIP-U Trial)
Joel M. Gelfand et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2020)
Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial
Luis Puig et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies
A. B. Kimball et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Evolution of pathologic T-cell subsets in patients with atopic dermatitis from infancy to adulthood
Tali Czarnowicki et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5
Desiree van der Heijde et al.
RHEUMATOLOGY (2020)
Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature
G. Caldarola et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasis
Lewis E. Tomalin et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Risk of tuberculosis reactivation during interleukin-17 inhibitor therapy for psoriasis: a systematic review
E. Fowler et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
The role of the interleukin-23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis
A. Egeberg et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review
A. Al-Janabi et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial
Christopher T Ritchlin et al.
LANCET (2020)
Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1)
K. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open-label CADMUS Jr study
S. Philipp et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Structural Analysis Reveals that the Cytokine IL-17F Forms a Homodimeric Complex with Receptor IL-17RC to Drive IL-17RA-Independent Signaling
Arnaud Goepfert et al.
IMMUNITY (2020)
Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials
Mark C. Genovese et al.
RHEUMATOLOGY (2020)
The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study
John W. Frew et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
Philip J. Mease et al.
LANCET (2020)
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial
Atul Deodhar et al.
LANCET (2020)
Evaluation of Ixekizumab Treatment for Patients With Pityriasis Rubra Pilaris A Single-Arm Trial
Dylan Haynes et al.
JAMA DERMATOLOGY (2020)
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
Laure Gossec et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Excessive Polyamine Generation in Keratinocytes Promotes Self-RNA Sensing by Dendritic Cells in Psoriasis
Fangzhou Lou et al.
IMMUNITY (2020)
Ustekinumab treatment is associated with decreased systemic and vascular inflammation in patients with moderate-to-severe psoriasis: Feasibility study using 18F-fluorodeoxyglucose PET/CT
Byung-Soo Kim et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
IL-17E (IL-25) Enhances Innate Immune Responses during Skin Inflammation
Luisa Senra et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
Imiquimod-Induced Psoriasis in Mice Depends on the IL-17 Signaling of Keratinocytes
Sonja Moos et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
Hectd3 promotes pathogenic Th17 lineage through Stat3 activation and Malt1 signaling in neuroinflammation
Jonathan J. Cho et al.
NATURE COMMUNICATIONS (2019)
Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa
L. Prussick et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition
M. Napolitano et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed
Grace Kimmel et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
CCL3, IL-7, IL-13 and IFNγ transcripts are increased in skin's biopsy of systemic sclerosis
Rafaela Silva Guimaraes Goncalves et al.
EXPERIMENTAL DERMATOLOGY (2019)
Anti-IL-17A and IL-23p19 antibodies but not anti-TNFα antibody induce expansion of regulatory T cells and restoration of their suppressive function in imiquimod-induced psoriasiform dermatitis
Teruo Shimizu et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2019)
c-Kit-positive ILC2s exhibit an ILC3-like signature that may contribute to IL-17-mediated pathologies
Jochem H. Bernink et al.
NATURE IMMUNOLOGY (2019)
Interleukin-17 receptor D constitutes an alternative receptor for interleukin-17A important in psoriasis-like skin inflammation
Yang Su et al.
SCIENCE IMMUNOLOGY (2019)
IL-12/IL-23 neutralization is ineffective for alopecia areata in mice and humans
Luana S. Ortolan et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Characteristic Pattern of IL-17RA, IL-17RB, and IL-17RC in Monocytes/Macrophages and Mast Cells From Patients With Bullous Pemphigoid
Stephane Nesmond et al.
FRONTIERS IN IMMUNOLOGY (2019)
Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-β
Juan Li et al.
SCIENCE IMMUNOLOGY (2019)
Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials
R. G. Langley et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
A role for Th1-like Th17 cells in the pathogenesis of inflammatory and autoimmune disorders
Ali N. Kamali et al.
MOLECULAR IMMUNOLOGY (2019)
RORγt inhibition selectively targets IL-17 producing iNKT and γδ-T cells enriched in Spondyloarthritis patients
Koen Venken et al.
NATURE COMMUNICATIONS (2019)
The role of epigenetics and immunological imbalance in the etiopathogenesis of psoriasis and psoriatic arthritis
Lukas Frischknecht et al.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2019)
Serum concentrations of IL-17A, IL-17B, IL-17E and IL-17F in patients with systemic sclerosis
Ewa Robak et al.
ARCHIVES OF MEDICAL SCIENCE (2019)
Ustekinumab treatment of pityriasis rubra pilaris: A report of five cases
Monica Napolitano et al.
JOURNAL OF DERMATOLOGY (2018)
IL-17 induces cellular stress microenvironment of melanocytes to promote autophagic cell apoptosis in vitiligo
Jia Zhou et al.
FASEB JOURNAL (2018)
An Interleukin-25-Mediated Autoregulatory Circuit in Keratinocytes Plays a Pivotal Role in Psoriatic Skin Inflammation
Miao Xu et al.
IMMUNITY (2018)
Gain-of-Function Mutation of Card14 Leads to Spontaneous Psoriasis-like Skin Inflammation through Enhanced Keratinocyte Response to IL-17A
Mingchao Wang et al.
IMMUNITY (2018)
The imbalance of circulating T helper subsets and regulatory T cells in patients with LRBA deficiency: Correlation with disease severity
Gholamreza Azizi et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2018)
A systematic review of ustekinumab in the treatment of atopic dermatitis
Yunlei Pan et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2018)
Neutralization of IL-17C Reduces Skin Inflammation in Mouse Models of Psoriasis and Atopic Dermatitis
Nick Vandeghinste et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
IL-17-Mediated Immunity Controls Skin Infection and T Helper 1 Response during Experimental Microsporum canis Dermatophytosis
Veronica L. Burstein et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study
Craig Leonardi et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Psoriasis and the risk of diabetes: A prospective population-based cohort study
Marilyn T. Wan et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial
Kim A. Papp et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Biologics for pityriasis rubra pilaris treatment: A review of the literature
Monica Napolitano et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Role of T helper 17 cells and T regulatory cells in alopecia areata: comparison of lesion and serum cytokine between controls and patients
S. -H. Loh et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2018)
Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5years of treatment (SCULPTURE Extension Study)
R. Bissonnette et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2018)
Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study
Atul Deodhar et al.
LANCET (2018)
Involvement of the IL23/Th17 Pathway in the Pathogenesis of Tunisian Pemphigus Foliaceus
M. Ben Jmaa et al.
MEDIATORS OF INFLAMMATION (2018)
Association of Hidradenitis Suppurativa With T Helper 1/T Helper 17 Phenotypes A Semantic Map Analysis
Rahel Thomi et al.
JAMA DERMATOLOGY (2018)
IL-1-IL-17 Signaling Axis Contributes to Fibrosis and Inflammation in Two Different Murine Models of Systemic Sclerosis
Min-Jung Park et al.
FRONTIERS IN IMMUNOLOGY (2018)
Efficacy and safety of secukinumab treatment in adults with extensive alopecia areata
Emma Guttman-Yassky et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2018)
Imbalance between T helper 17 and regulatory T cell subsets plays a significant role in the pathogenesis of systemic sclerosis
Cuiling Mo et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
Kenneth B. Gordon et al.
LANCET (2018)
Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation
Sophie Glatt et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study
Eleni Kampylafka et al.
ARTHRITIS RESEARCH & THERAPY (2018)
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
Philip J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study
K. Yamasaki et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis
Saakshi Khattri et al.
EXPERIMENTAL DERMATOLOGY (2017)
β-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis
Frank Kolbinger et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Potential role of IL-17-producing CD4/CD8 double negative αβ Tcells in psoriatic skin inflammation in a TPA-induced STAT3C transgenic mouse model
Azumi Ueyama et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2017)
IL-17A-Induced PLET1 Expression Contributes to Tissue Repair and Colon Tumorigenesis
Jarod A. Zepp et al.
JOURNAL OF IMMUNOLOGY (2017)
Hidradenitis Suppurativa Is Characterized by Dysregulation of the Th17:Treg Cell Axis, Which Is Corrected by Anti-TNF Therapy
Barry Moran et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2017)
Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data
Bruce Strober et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents
Lukasz Matusiak et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
Peter Nash et al.
LANCET (2017)
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
Kristian Reich et al.
LANCET (2017)
Th1/Th17-Related Cytokines and Chemokines and Their Implications in the Pathogenesis of Pemphigus Vulgaris
Rodolfo Pessato Timoteo et al.
MEDIATORS OF INFLAMMATION (2017)
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
Kim A. Papp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study
Iain B. McInnes et al.
RHEUMATOLOGY (2017)
Interleukin 23-Helper T Cell 17 Axis as a Treatment Target for Pityriasis Rubra Pilaris
Laurence Feldmeyer et al.
JAMA DERMATOLOGY (2017)
IL-17A localizes in the exocytic compartment of mast cells in psoriatic skin
N. C. Brembilla et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Interleukin (IL)-17A and IL-22-producing neutrophils in psoriatic skin
B. Dyring-Andersen et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: a randomized, double-blind, placebo-controlled, phase II study
H. Saeki et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management
D. M. Saunte et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris
A. Chiricozzi et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Keratinocytes and neutrophils are important sources of proinflammatory molecules in hidradenitis suppurativa
A. L. Lima et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
T-helper 17 cytokines (interleukins 17, 21, 22, and 6, and tumor necrosis factor-) in patients with alopecia areata: association with clinical type and severity
Mona A. Atwa et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2016)
Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum
J. L. Blok et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
IL-17 Receptor Signaling in Oral Epithelial Cells Is Critical for Protection against Oropharyngeal Candidiasis
Heather R. Conti et al.
CELL HOST & MICROBE (2016)
The Costimulatory Receptor OX40 Inhibits Interleukin-17 Expression through Activation of Repressive Chromatin Remodeling Pathways
Xiang Xiao et al.
IMMUNITY (2016)
Keratinocyte-Derived IL-17E Contributes to Inflammation in Psoriasis
Luisa Senra et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2016)
Chronic skin inflammation leads to bone loss by IL-17-mediated inhibition of Wnt signaling in osteoblasts
Oezge Uluckan et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Tiam1/Rac1 complex controls Il17a transcription and autoimmunity
Ahmed T. Kurdi et al.
NATURE COMMUNICATIONS (2016)
IL-17-producing γδ T cells enhance bone regeneration
Takehito Ono et al.
NATURE COMMUNICATIONS (2016)
Successful Treatment of Refractory Pityriasis Rubra Pilaris With Secukinumab
Daniel Schuster et al.
JAMA DERMATOLOGY (2016)
Mutual upregulation of endothelin-1 and IL-25 in atopic dermatitis
M. K. Aktar et al.
ALLERGY (2015)
Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa
Alex Anstey
BRITISH JOURNAL OF DERMATOLOGY (2015)
The elevated expression of Th17-related cytokines and receptors is associated with skin lesion severity in early systemic sclerosis
Yan Zhou et al.
HUMAN IMMUNOLOGY (2015)
Growth Factor FGF2 Cooperates with Interleukin-17 to Repair Intestinal Epithelial Damage
Xinyang Song et al.
IMMUNITY (2015)
The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization
Shinji Noda et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)
Human mast cells are major IL-22 producers in patients with psoriasis and atopic dermatitis
Shunya Mashiko et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)
Imbalance of T-helper 17 and regulatory T cells in patients with alopecia areata
Yu-Mei Han et al.
JOURNAL OF DERMATOLOGY (2015)
A novel IL-17 signaling pathway controlling keratinocyte proliferation and tumorigenesis via the TRAF4-ERK5 axis
Ling Wu et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Melanocyte antigen triggers autoimmunity in human psoriasis
Akiko Arakawa et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Syk Mediates IL-17-Induced CCL20 Expression by Targeting Act1-Dependent K63-Linked Ubiquitination of TRAF6
Nan-Lin Wu et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Dissecting susceptibility from exogenous triggers: the model of alopecia areata and associated inflammatory skin diseases
N. Garzorz et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2015)
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
Iain B. McInnes et al.
LANCET (2015)
TH17 cells promote microbial killing and innate immune sensing of DNA via interleukin 26
Stephan Meller et al.
NATURE IMMUNOLOGY (2015)
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
Philip J. Mease et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Enhanced meta-analysis and replication studies identify five new psoriasis susceptibility loci
Lam C. Tsoi et al.
NATURE COMMUNICATIONS (2015)
Comparative Genomic Profiling of Synovium Versus Skin Lesions in Psoriatic Arthritis
Jennifer Belasco et al.
ARTHRITIS & RHEUMATOLOGY (2015)
IL-17A gene transfer induces bone loss and epidermal hyperplasia associated with psoriatic arthritis
Iannis E. Adamopoulos et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Interleukin 17 Drives Vascular Inflammation, Endothelial Dysfunction, and Arterial Hypertension in Psoriasis-Like Skin Disease
Susanne Karbach et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2014)
Composition of Innate Lymphoid Cell Subsets in the Human Skin: Enrichment of NCR+ ILC3 in Lesional Skin and Blood of Psoriasis Patients
Marcel B. M. Teunissen et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Innate Immune Cell-Produced IL-17 Sustains Inflammation in Bullous Pemphigoid
Sebastien Le Jan et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Overexpression of Interleukin-23 and Interleukin-17 in the Lesion of Pemphigus Vulgaris: A Preliminary Study
Jixin Xue et al.
MEDIATORS OF INFLAMMATION (2014)
Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials
Richard G. Langley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Increased frequency of Th17 cells in systemic sclerosis is related to disease activity and collagen overproduction
Xiaoqin Yang et al.
ARTHRITIS RESEARCH & THERAPY (2014)
Interleukin-17A promotes functional activation of systemic sclerosis patient-derived dermal vascular smooth muscle cells by extracellular-regulated protein kinases signalling pathway
Mengguo Liu et al.
ARTHRITIS RESEARCH & THERAPY (2014)
Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?
Lisa G. M. van Baarsen et al.
ARTHRITIS RESEARCH & THERAPY (2014)
The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis
Roberto Lande et al.
NATURE COMMUNICATIONS (2014)
Structure of the unique SEFIR domain from human interleukin 17 receptor A reveals a composite ligand-binding site containing a conserved α-helix for Act1 binding and IL-17 signaling
Bing Zhang et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2014)
Myeloid marker S100A8/A9 and lymphocyte marker, soluble interleukin 2 receptor: biomarkers of hidradenitis suppurativa disease activity?
C. W. Wieland et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
T-helper and regulatory T-cell cytokines in the peripheral blood of patients with active alopecia areata
M. K. Tembhre et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis
Mayte Suarez-Farinas et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)
A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis
Maryam Salimi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Keratinocyte Overexpression of IL-17C Promotes Psoriasiform Skin Inflammation
Andrew Johnston et al.
JOURNAL OF IMMUNOLOGY (2013)
The Deubiquitinase A20 Mediates Feedback Inhibition of Interleukin-17 Receptor Signaling
Abhishek V. Garg et al.
SCIENCE SIGNALING (2013)
Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis
Troy Noordenbos et al.
ARTHRITIS AND RHEUMATISM (2012)
Alterations in leucocyte subsets and histomorphology in normal-appearing perilesional skin and early and chronic hidradenitis suppurativa lesions
H. H. van der Zee et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
IL-17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion
Danuta Gutowska-Owsiak et al.
EXPERIMENTAL DERMATOLOGY (2012)
IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis
James G. Krueger et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2012)
Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis
Julia K. Gittler et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2012)
IL-17 receptor and its functional significance in psoriatic arthritis
Siba P. Raychaudhuri et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2012)
Pivotal Role of Dermal IL-17-Producing γδ T Cells in Skin Inflammation
Yihua Cai et al.
IMMUNITY (2011)
IL-25 in Atopic Dermatitis: A Possible Link between Inflammation and Skin Barrier Dysfunction?
Malene Hvid et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2011)
Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa
Christoph Schlapbach et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2011)
Treatment with IL-17 prolongs the half-life of chemokine CXCL1 mRNA via the adaptor TRAF5 and the splicing-regulatory factor SF2 (ASF)
Dongxu Sun et al.
NATURE IMMUNOLOGY (2011)
The inducible kinase IKKi is required for IL-17-dependent signaling associated with neutrophilia and pulmonary inflammation
Katarzyna Bulek et al.
NATURE IMMUNOLOGY (2011)
Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity
Anne Puel et al.
SCIENCE (2011)
Serum cytokines and growth factor levels in Japanese patients with psoriasis
H. Takahashi et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2010)
SEF/IL-17R (SEFIR) Is Not Enough AN EXTENDED SEFIR DOMAIN IS REQUIRED FOR IL-17RA-MEDIATED SIGNAL TRANSDUCTION
Reiko M. Onishi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Modulation of experimental autoimmune encephalomyelitis through TRAF3-mediated suppression of interleukin 17 receptor signaling
Shu Zhu et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines
Kai Kisand et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
IL-17RC Is Required for Immune Signaling via an Extended SEF/IL-17R Signaling Domain in the Cytoplasmic Tail
Allen W. Ho et al.
JOURNAL OF IMMUNOLOGY (2010)
Overrepresentation of IL-17A and IL-22 Producing CD8 T Cells in Lesional Skin Suggests Their Involvement in the Pathogenesis of Psoriasis
Pieter C. M. Res et al.
PLOS ONE (2010)
Innate IL-17-producing cells: the sentinels of the immune system
Daniel J. Cua et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin
C. Johansen et al.
BRITISH JOURNAL OF DERMATOLOGY (2009)
Filaggrin-deficient mice exhibit TH17-dominated skin inflammation and permissiveness to epicutaneous sensitization with protein antigen
Michiko K. Oyoshi et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2009)
Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis
Emma Guttman-Yassky et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2009)
IL-22-producing T22 T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells
Kristine E. Nograles et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2009)
Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8
Dipyaman Ganguly et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Th17 Cytokines Stimulate CCL20 Expression in Keratinocytes In Vitro and In Vivo: Implications for Psoriasis Pathogenesis
Erin G. Harper et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides
Camilla Jandus et al.
ARTHRITIS AND RHEUMATISM (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L. Leonardi et al.
LANCET (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Kim A. Papp et al.
LANCET (2008)
Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide
Roberto Lande et al.
NATURE (2007)
Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1/2-dependent NF-κB and C/EBP β activation
Devang N. Patel et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Identification of an interleukin 17F/17A heterodimer in activated human CD4+T cells
Jill F. Wright et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis
Yan Zheng et al.
NATURE (2007)
The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease
Youcun Qian et al.
NATURE IMMUNOLOGY (2007)
Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor
Seon Hee Chang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17
H Park et al.
NATURE IMMUNOLOGY (2005)
Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis
MI Koenders et al.
ARTHRITIS AND RHEUMATISM (2005)
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation
CL Langrish et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Increased expression of interleukin 17 in inflammatory bowel disease
S Fujino et al.
GUT (2003)
Share Paper
